Clinical trial
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor…
NCT00045032 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00045032 |
|---|---|
| Title | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer |
| Official title | A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy |
| Acronym | HERA |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Breast International Group European Organisation for Research and Treatment of Cancer - EORTC NCIC Clinical Trials Group ETOP IBCSG Partners Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin |
| Enrollment | 5,099 |
| Start date | Nov 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Jun 1, 2015 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 27, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Denmark, France and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: